AGING AND HUMAN ENDOCRINE REGULATION

我们研究了12名65岁健康男性的夜间睡眠和夜间活动 GH分泌谱，以及糖耐量，IGF-I，T， 骨钙素、脂类和骨生化(尿吡啶 交叉连接，和钙)，身体成分，肌肉力量和 核磁共振对高能磷酸盐的利用，都是在 GHRH 1-29皮下注射，每晚1次，连用6周。那里 注射GHRH后GH分泌显著增加，平均 血清IGF-I水平，以及肌肉力量和显著下降 糖耐量曲线下面积和低密度脂蛋白，但没有变化 在甘油三酯或高密度脂蛋白胆固醇和无明显疗效的治疗 身体质量指数、其他人体测量指标或骨骼指标 新陈代谢。160例男性高血压患者6个月治疗效果的研究 65岁的女性服用生长激素和性激素，或同时服用，或不服用多种药物。 相关的临床和生理终点已经启动，并且 正在进行中。

We studied 12 healthy men >65 years old overnight for sleep and nocturnal GH secretory profiles, as well as for glucose tolerance,IGF-I,T, osteocalcin, lipid profiles, and bone biochemistries (urine pyridinoline cross-links, and calcium), body composition, muscle strength and utilization of high energy phosphate by NMR, all before and at the end of a regimen of GHRH 1-29 self-injected sc once nightly for 6 weeks. There was a significant increase in GH secretion after GHRH injections, in mean serum IGF-I levels, and in muscle strength and significant decreases in area under glucose tolerance curves and in LDL cholesterol, but no changes in triglycerides or HDL cholesterol and no apparent effect of treatment on body mass index, other anthropometric measures or measures of bone metabolism. A study of the effects of 6 months of treatment of 160 men and women >65 years with rhGH, sex steroid, both, or neither on multiple relevant clinical and physiologic end-points has been initiated and is ongoing.